Udaya Rangaswamy
Senior Director - Translational Biology Rondo Therapeutics
Dr. Udaya Rangaswamy is Senior Director of Translational Biology at Rondo Therapeutics. She previously served as a Principal Scientist at Amgen following its acquisition of Teneobio, where she contributed to multiple heme-oncology programs progressing T-cell engager molecules from lead optimization into clinical trials. Her prior postdoctoral work at MedImmune/AstraZeneca focused on oncolytic virotherapy mechanisms, and she holds a PhD in microbiology and molecular genetics from Emory University.
Seminars
Wednesday 24th June 2026
Panel Discussion: Standardizing Safety Benchmarks by Establishing Collaborative In Vitro Frameworks to De- Risk T-Cell Engager Translation
2:30 pm
- Addressing the lack of commercialized GLP-standardized assays for pHLA and human-specific targets, and the resulting necessity for companies to develop bespoke, creative in-house solutions
- Evaluating current industry best practices by analyzing the non-clinical pathways of pioneers to establish a common technical foundation for the field
- Proposing collaborative strategies to share methodologies and validation data for in vitro assays to help move the industry toward a unified standard that can be more effectively presented to regulatory bodies
Tuesday 23rd June 2026
Harnessing Precision Synapse Engineering by Designing Condition Specific Co- Stimulation to Advance Therapeutic Windows
8:30 am
Join this workshop to navigate the engineering trade-offs required to unlock the potential of costimulatory engagers in solid tumors.
- Discussing criteria for the selection of high value targets that require conditional activation to protect healthy tissue
- Analyzing the pros and cons of masking the TAA binder versus the CD3 binder
- Identifying the most robust protease-cleavable linkers and stable building blocks
- Discussing models to stimulate the human TME protease levels
- Strategies for evaluating the PK of post-cleaved active product vs pro-drug masked state
- Defining minimum preclinical data set required to justify the complexity of a conditional molecule over a regular one
Wednesday 24th June 2026
Engineering Co-Stimulation for Mitigating Systemic Toxicity & Maximising Localized T-Cell Activation
11:30 am
- Evaluating risk-benefit profile associated with systemic costimulatory receptor engagement
- Analyzing molecular design where co-stimulatory activation depends on signal 1 engagement to ensure T-cell proliferation is restricted to the tumor antigen surface
- Examining how tumor associated antigen effects efficacy and cytokine release
